logo-loader
RNS
Ondine Biomedical Inc

Ondine Biomedical - Steriwave Now Protecting Patients with Cancer

RNS Number : 3369A
Ondine Biomedical Inc.
23 September 2025
 

23 September 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Steriwave Now Protecting Patients with Cancer

The Mater Hospital, North Sydney, Adopts Steriwave to Combat AMR in Cancer Care

·   Antimicrobial resistance (AMR) is driving higher mortality, morbidity, and healthcare costs for patients with cancer.

·    Hospitalized patients with cancer face up to twice the risk of antibiotic-resistant infections.

·   AMR pathogens are up to three times as prevalent in outpatients with cancer compared with patients without cancer.

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated, non-antibiotic infection prevention therapies, announces that The Mater Hospital, North Sydney, has introduced Steriwave® nasal photodisinfection into its oncology program to help combat the growing threat of antimicrobial resistance (AMR) in cancer care. Mounting evidence shows people with cancer face significantly higher risks from drug-resistant infections-a challenge the hospital is determined to address head-on.

Patients with cancer, particularly those undergoing chemotherapy, radiation, stem cell transplants or surgery, are highly vulnerable to infection due to weakened immune systems and frequent healthcare exposure. These risks are magnified by the rise of antibiotic-resistant bacteria.

Recent studies underscore these risks:

·    Hospitalized patients with cancer face 1.5 to 2 times higher rates of AMR infections than other inpatients (Gupta et al., Cancer Medicine, 2024).

·     Outpatients with cancer experience up to 3 times higher rates of AMR pathogens, such as VRE (vancomycin-resistant enterococci), ESBL-producing Enterobacterales, and carbapenem-resistant Pseudomonas (Gupta et al., Lancet Oncology, 2025).

·     In patients with hematologic malignancies, AMR infections occur in up to 35% of cases and are closely linked with increased mortality (Sallah et al., Lancet Oncology, 2025).

Steriwave is a non-invasive and painless treatment that uses a proprietary light-activated photosensitive agent to destroy harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in the nasal passages. The procedure takes five minutes and, unlike antibiotics, is effective immediately and allows the normal nasal microbiome to recover quickly, without fostering antimicrobial resistance.

Carolyn Cross, CEO of Ondine Biomedical:

"We are pleased to collaborate with Professor Boyle and the Mater team to bring Steriwave to people battling cancer. This marks an important step in expanding Steriwave's role beyond surgical and ICU settings into broader cancer care, where the need is increasingly urgent."

A Cost-Effective and Life-Saving Strategy

The challenge:

·  Resistant infections drive up costs through prolonged hospital stays, expensive last-line antibiotics, and added staffing requirements.

·   AMR increases morbidity and mortality by delaying or disrupting life-saving treatments like chemotherapy or transplants.

·      Health equity gaps widen in settings with limited access to advanced antibiotics and diagnostics (Shropshire & Shelburne, Lancet Oncology, 2025).

How Steriwave helps:

·   Steriwave reduces infection rates, shortening hospital stays and lowering reliance on costly drugs.

·    Preventing resistant infections allows patients to stay on schedule with critical cancer therapies.

·    As a non-antibiotic, low-cost intervention, Steriwave supports more equitable access to infection prevention worldwide.

As AMR continues to rise globally, incorporating preventive innovations like Steriwave into oncology care can help protect people with cancer, sustain life-saving treatments, and ease growing pressures on healthcare systems.

 

About The Mater Hospital, North Sydney

The Mater Hospital, North Sydney, part of St Vincent's Health Australia, is a leading not-for-profit hospital providing compassionate, high-quality care across oncology, surgery, palliative care, and other specialties. The hospital's Patricia Ritchie Centre for Cancer Care and Research is internationally recognized for excellence in oncology and commitment to innovation that improves patient outcomes.

St Vincent's operates 10 private hospitals across New South Wales (three), Victoria (four), and Queensland (three), serving both metropolitan and regional communities. St Vincent's private hospitals have been ranked first for five years in a row by Medibank's overnight patient customers in all 10 categories surveyed, reflecting its consistently high standard of patient care and experience.

 

Enquiries:

Ondine Biomedical Inc.

www.ondinebio.com

Carolyn Cross, CEO 

+1 604 669 0555
or via Vane Percy & Roberts

 

Strand Hanson Limited (Nominated & Joint Financial Adviser)


James Harris, Richard Johnson

+44 (0)20 7409 3494



Peel Hunt LLP (Broker & Joint Financial Advisor)


James Steel, Dr. Chris Golden

+44 (0)20 7418 8900



Vane Percy & Roberts (Media Contact)


Simon Vane Percy

+44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPKBBPKBKBACB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Ondine Biomedical, Bezant Resources, Vaultz Capital, Petra Diamonds, Huddled...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has reported a 51.5% drop in surgical-site infections at Canada’s largest cardiac centre after introducing Steriwave. It adds real-world evidence to its Phase 3 LANTERN results. Read more Bezant Resources PLC (AIM:BZT) has secured a £4 million loan...

3 weeks, 6 days ago

5 min read